Several pathological conditions as autoimmune and inflammatory diseases are due to an excessive T cell activity. Treatment modalities are based on the relief from symptoms, whereby immune suppressive biologicals are rapidly expanding, owing to the good efficacy and safety profiles. However, for the regulation of the starting point of the disease-causing processes no agents exist until now. For that we offer a new agent with an exceptional stringent and specific suppression of T cell activation, whereby the inactivation is reversible. With this invention it is not only possible to address T cells in their entirety, but also antigen-specific T cells. Membrane mobility characteristics have not to be considered, because the target is located on the outside of T cells.
Further information: PDF
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
firstname.lastname@example.org | TechnologieAllianz e.V.
Quat primer polymers the universal key to permanent surface functionalization
27.02.2017 | TechnologieAllianz e.V.
Novel carbonization process of PAN-nanofiber mats with enhanced surface area and porosity
20.02.2017 | TechnologieAllianz e.V.
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
27.02.2017 | Materials Sciences
27.02.2017 | Interdisciplinary Research
27.02.2017 | Life Sciences